Actually, there were two patent applications, one of which indicates that Libigel's sexual dysfunction target is still on the table. Both applications also target Cardiovascular disease.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.